1.
The Daily Costs of Chemotherapy-Associated Adverse Events: A ...
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer.
2.
Phase I and pharmacokinetic study of kanglaite injection (KLT) a ...
Phase I and pharmacokinetic study of kanglaite injection (KLT) a botanical product based on traditional Chinese medicine. ...
3.
Phase I study of kanglaite (KLT) a botanical product based on ...
Phase I study of kanglaite (KLT) a botanical product based on traditional Chinese ... Salt Lake City, UT, Albania; Kanglaite USA, Salt Lake City, UT ...
4.
Phase II Study of Pacitaxel in Non-Hodgkin's Lymphoma And Long ...
Sixteen patients with relapsing or refactory non-Hodgkin's lymphoma were treated with pacitaxel as a single agent at a dose of 175mg/m2 by a 3-hour IV ...
5.
Clinical outcome of expectantly managed early prostate cancer: A ...
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer.
6.
Systolic and diastolic dysfunction in childhood cancer survivors ...
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer.
7.
Cost-effectiveness of docetaxel compared to paclitaxel in ...
The discounted Incremental Cost-Effectivness Ratio (ICER) of docetaxel vs paclitaxel 3-weekly was estimated to be £5532/LY gained (95% CI 2250-12700) and ...
8.
Nadaplatin or cisplatin combined with paclitaxol in treating non ...
However, no randomized clinical trial has been done compared with cisplatin when combined with paclitaxol in treating non-small cell lung cancer. ...
9.
Prevention of peripheral neuropathy from paclitaxel and ...
Purpose: Peripheral neuropathy is dose-limiting effect in paclitaxel therapy. Treatment with non-steroidal anti-inflammatory drugs, narcotic analgesics, ...
10.
An open-label, phase II trial of nanoparticle albumin bound ...
In this open label, phase II trial, patients with advanced (stage IIIB or IV) nonsquamous NSCLC received the combination of nab-paclitaxel, carboplatin and ...
